Omada Health, Inc.
OMDA- Exchange
- Nasdaq
- Industry
- Services-Health Services
- SEC CIK
- 0001611115
In the last 90 days, Omada Health, Inc. insiders filed 0 open-market purchases and 9 sales; 153 institutions reported holding it in 13F filings for Q2 2026, worth $1.15B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:54 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $12.8M (4.9% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 |
|---|---|
| Period end | Dec 31, 2025 |
| Filing | 10-K |
| Reported | Jan 12, 2026 |
| Revenue | $260.2M |
| Cost of revenue | $89.3M |
| Gross profit | $170.9M |
| Operating expenses | $182.9M |
| Research and development | $40.7M |
| Selling, general and administrative | $52.2M |
| Operating income | -$12.0M |
| Income tax | $0 |
| Net income | -$12.8M |
| EPS, basic | $-0.35 |
| EPS, diluted | $-0.35 |
| Weighted shares, basic | 36.6M |
| Weighted shares, diluted | 36.6M |
| Margins and growth | |
| Gross margin | 65.7% |
| Operating margin | -4.6% |
| Net margin | -4.9% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 |
|---|---|
| Period end | Dec 31, 2025 |
| Filing | 10-K |
| Reported | Jan 12, 2026 |
| Cash and equivalents | $222.0M |
| Accounts receivable | $34.6M |
| Inventory | $4.49M |
| Total current assets | $272.9M |
| Property, plant and equipment | $7.94M |
| Goodwill | $13.2M |
| Intangible assets | $2.41M |
| Total assets | $305.4M |
| Accounts payable | $10.3M |
| Total current liabilities | $75.7M |
| Long-term debt | $0 |
| Total liabilities | $75.7M |
| Shareholders' equity | $229.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 |
|---|---|
| Period end | Dec 31, 2025 |
| Filing | 10-K |
| Reported | Jan 12, 2026 |
| Operating cash flow | $18.3M |
| Capital expenditures | $1.32M |
| Free cash flow | $16.9M |
| Depreciation and amortization | $5.49M |
| Stock-based compensation | $13.0M |
| Investing cash flow | -$5.83M |
| Financing cash flow | $133.2M |
| Net change in cash | $145.6M |
| Ratio | |
| Stock-based compensation, % of revenue | 5.0% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.